<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968498</url>
  </required_header>
  <id_info>
    <org_study_id>Lact-001-CEN</org_study_id>
    <nct_id>NCT02968498</nct_id>
  </id_info>
  <brief_title>Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers</brief_title>
  <official_title>Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open, mono-center, randomized, two part study with 4-way cross-over design in
      each study part.

      The objective of the study is to investigate blood glucose levels after oral intake of
      defined amounts of lactulose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capillary blood glucose levels as incremental area under the curve (iAUC) above baseline (iAUC(0-180min))</measure>
    <time_frame>0-180 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum blood glucose concentration (Cmax)</measure>
    <time_frame>0-180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum increase of blood glucose concentration (Max_increase)</measure>
    <time_frame>0-180 min</time_frame>
    <description>Cmax minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative maximum increase of blood glucose concentration(Max_increase rel)</measure>
    <time_frame>0-180 min</time_frame>
    <description>Cmax / baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum blood glucose concentration (Tmax)</measure>
    <time_frame>0-180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First time to reach baseline again after increase or decrease in blood glucose (Tbaseline)</measure>
    <time_frame>0-180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total area under curve from 0 to 180 min for blood glucose concentration (AUC(0-180min))</measure>
    <time_frame>0-180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline corrected area under curve from 0 to 180 min for blood glucose concentration (AUCbase_c(0-180min))</measure>
    <time_frame>0-180 min</time_frame>
    <description>Area under curve from 0 to 180 min minus baseline*180min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>After screening till study day 22 (+24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerability (assessed by subject's questionnaire)</measure>
    <time_frame>180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerability (assessed by subject's questionnaire)</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Blood Glucose</condition>
  <arm_group>
    <arm_group_label>Study arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactulose crystals 10 g</intervention_name>
    <description>White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Study arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactulose crystals 20 g</intervention_name>
    <description>White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Study arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactulose liquid 10 g</intervention_name>
    <description>Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Study arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactulose liquid 20 g</intervention_name>
    <description>Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Study arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral glucose 20 g</intervention_name>
    <description>White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Study arm 1</arm_group_label>
    <arm_group_label>Study arm 2</arm_group_label>
    <other_name>glucose monohydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Still water</intervention_name>
    <description>Still water will be used. Water from the same source will be also used to dissolve investigational and control products.</description>
    <arm_group_label>Study arm 1</arm_group_label>
    <arm_group_label>Study arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age: 18-65 years

          -  Approx. 3-5 bowel movements per week

          -  Caucasian

          -  Availability and presence in the trial unit for approx. 4 hours/ week for 4 times in a
             row with approx. 1 week of washout in between

          -  Signed informed consent form

        Exclusion Criteria:

          -  Known (family) history of diabetes mellitus or use of anti-hyperglycaemic drugs or
             Insulin

          -  Clinically relevant renal or hepatic disease, liver enzymes &gt; 10% above reference
             range

          -  Fasting blood glucose &gt; 100 mg/dL or HbA1c outside of reference range

          -  Total cholesterol &gt; 250 mg/dL or triglycerides &gt; 150 mg/dL

          -  Haemoglobin &lt; 11 g/dL (women); &lt; 12.5 g/dL (men)

          -  BMI &lt; 19 kg/m² and ≥ 30 kg/m²

          -  Intentional and unintentional weight loss &gt; 5% in the previous 6 months

          -  Smoker

          -  Major medical or surgical event requiring hospitalization within the previous 3 months

          -  Presence of disease or drug(s) influencing digestion and absorption of nutrients or
             bowel habits

          -  Intake of medications known to affect glucose tolerance, e.g., steroids, protease
             inhibitors or antipsychotics (stable doses of e.g., oral contraceptives, thyroxin,
             vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are
             acceptable)

          -  Chronic intake of substances affecting blood coagulation (e.g. acetylic acid,
             anticoagulants, diuretics, thiazides), which in the investigator's opinion would
             impact volunteer safety

          -  Hereditary problems of galactose or fructose intolerance, lactase deficiency or
             glucose-galactose malabsorption

          -  Suspicion of drug abuse

          -  Abuse of alcoholic drinks, defined as an average daily intake of more than one litre
             of beer per day or equivalent amount of alcohol in other beverages

          -  Pregnant or breast feeding women

          -  Known or suspected allergy to any component of the investigational product(s)

          -  Known HIV-infection

          -  Known acute or chronic hepatitis B and C infection

          -  Blood donation within 4 weeks prior to visit 1 or during the study

          -  Volunteer unable to co-operate adequately

          -  Participation in a clinical trial with an investigational product within one month
             before start of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Menzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRO BioTeSys GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRO BioTeSys GmbH</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood glucose level</keyword>
  <keyword>Oral intake</keyword>
  <keyword>Lactulose</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

